Symantec Corporation (NASDAQ:SYMC) shares decreased -0.30% in last trading session and ended the day at $19.94. SYMC Gross Margin is 82.40% and its has a return on assets of 5.20%. Symantec Corporation (NASDAQ:SYMC) quarterly performance is 0.40%.
Symantec Corporation (NASDAQ:SYMC) has declared a quarterly cash dividend of $0.15 per common share to be paid on December 16, 2015 to all shareholders of record as of the close of business on November 23, 2015. The ex-dividend date will be November 19, 2015.
BioLife Solutions Inc (NASDAQ:BLFS) ended the last trading day at $2.23. Company weekly volatility is calculated as 5.14% and price to cash ratio as 5.15. BioLife Solutions Inc (NASDAQ:BLFS) showed a weekly performance of -1.76%.
On 16 November, BioLife Solutions Inc (NASDAQ:BLFS) announced that it has been named to the Deloitte 2015 Technology Fast 500, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors.
KeyCorp (NYSE:KEY) caters to the Financial space. It has a net profit margin of 35.50% and weekly performance is 2.51%. On the last day of trading company shares ended up at $13.08. KeyCorp (NYSE:KEY) distance from 50-day simple moving average (SMA50) is -0.42%.
KeyCorp (NYSE:KEY) announced that Chairman and Chief Executive Officer Beth E. Mooney and Chief Financial Officer Don Kimble will present at the Goldman Sachs U.S. Financial Services Conference in New York City on Tuesday, December 8, 2015, at 11:30 a.m. ET.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) shares moved down -2.88% in last trading session and ended the day at $12.48. ZIOP has a return on assets of -102.10%. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) quarterly performance is 57.18%.
On 19 November, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced that the Company is presenting initial results from an ongoing Phase 1 dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant glioma.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) caters to the Healthcare space. Its weekly performance is -14.13%. On the last day of trading company shares ended up at $2.37. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) distance from 50-day simple moving average (SMA50) is 6.94%.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) was downgraded by Zacks from a “buy” rating to a “hold” rating in a research report issued on Monday, Analyst Ratings Network.com reports.